Skip to main content
. 2016 Mar 17;7(14):17532–17546. doi: 10.18632/oncotarget.8162

Figure 2. IRF4 expression regulated by FoxO1 in IL-4 stimulated macrophages.

Figure 2

A. Pretreatment with AS1842856, a selective FoxO1 inhibitor blunted the upregulation of IRF4 transcript in IL-4-activated MH-S alveolar macrophages. B. qPCR analysis of IRF4 in bone marrow derive macrophages (BMDM) and peritoneal macropahges (PM) from WT and LysMFoxO1KO mice. C. qPCR analysis of IRF4 by IL-4 stimulated M2 macrophages infected with an adenovirus expressing either GFP or FoxO1 TSS (where TSS is a mutant containing the mutations T24A, S256A and S319A). D. qPCR analysis of IRF4 in IL-4 stimulated BMDM of LysMFoxO1Tg mice. E. ChIP assay of FoxO1 binding to Irf4 promoter constructs in MH-S alveolar macrophages in the presence or absence of AS1842856. All results are normalized to IgG. Data are representative of at least two independent experiments (A-E). *p < 0.05, **p < 0.01, ***p < 0.001 versus nontreated, #p < 0.05, ##p < 0.01, ###p < 0.001 vs. IL-4 with noninhibitor, $p < 0.05 vs. IL-4 treated WT (student's t-test).

HHS Vulnerability Disclosure